Nomura Asset Management Co. Ltd. Has $3.21 Million Position in Catalent, Inc. (NYSE:CTLT)

Nomura Asset Management Co. Ltd. grew its holdings in Catalent, Inc. (NYSE:CTLT) by 1.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 53,011 shares of the company’s stock after purchasing an additional 750 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Catalent were worth $3,211,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Athos Capital Ltd acquired a new stake in shares of Catalent during the 3rd quarter worth approximately $6,009,000. State Street Corp grew its stake in shares of Catalent by 1.5% in the 3rd quarter. State Street Corp now owns 7,451,135 shares of the company’s stock valued at $451,315,000 after buying an additional 113,095 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Catalent in the third quarter valued at approximately $1,131,000. Sumitomo Mitsui Trust Group Inc. grew its position in Catalent by 3.7% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock valued at $24,550,000 after purchasing an additional 14,373 shares during the period. Finally, Quest Partners LLC increased its position in shares of Catalent by 289.8% during the third quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock worth $2,986,000 after acquiring an additional 36,652 shares in the last quarter.

Insider Transactions at Catalent

In related news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,114 shares of company stock valued at $305,931 over the last three months. Company insiders own 0.31% of the company’s stock.

Catalent Trading Up 0.0 %

Shares of Catalent stock opened at $63.07 on Friday. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51. The stock has a market capitalization of $11.45 billion, a P/E ratio of -27.91, a P/E/G ratio of 2.70 and a beta of 1.15. Catalent, Inc. has a 52-week low of $40.29 and a 52-week high of $63.25. The stock’s 50-day simple moving average is $60.30 and its 200 day simple moving average is $59.00.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the company posted ($0.10) earnings per share. The business’s quarterly revenue was up 4.2% compared to the same quarter last year. As a group, research analysts anticipate that Catalent, Inc. will post 0.78 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CTLT shares. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. StockNews.com downgraded shares of Catalent from a “hold” rating to a “sell” rating in a report on Tuesday, December 10th. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating and seven have assigned a hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.